Wellgistics Health, Inc. (NASDAQ:WGRX) introduced Forzet, a medical‑food product designed to counter muscle loss in patients receiving GLP‑1 agonist weight‑loss therapies. The launch, announced on March 9 2026, positions Forzet within the $70 billion GLP‑1 market, which is projected to expand to $201 billion by 2030.
Forzet targets a side effect that can undermine the long‑term success of GLP‑1 drugs: loss of lean body mass, which can account for 12‑40 % of total weight loss and may contribute to weight regain after discontinuation. By providing a specialized nutritional blend, Forzet seeks to preserve muscle mass and support sustained weight management. The medical‑food market is expected to reach $40 billion by 2034, offering a sizable opportunity for a product that addresses a clinically relevant gap.
The launch comes as Wellgistics faces a challenging financial backdrop. In the third quarter of 2025 the company reported a net loss of $34.3 million on revenue of $3.0 million, a decline of 414 % and 61 % from the prior quarter, respectively. The company’s stock has also slipped sharply over the past year, reflecting investor concerns about its ability to generate consistent earnings.
Prashant Patel, President and Interim‑CEO, highlighted the company’s focus on operational execution and the rollout of its EinsteinRx AI platform in 2026. He noted that Forzet’s role in addressing muscle loss is a key component of the company’s strategy to strengthen its value proposition to independent pharmacies, where the product will be distributed through the EinsteinRx platform and the PharmacyChain blockchain ecosystem.
While Forzet offers a potentially high‑impact solution in a growing market, its success will hinge on Wellgistics’ ability to scale distribution, manage costs, and navigate the company’s current financial constraints. The product launch represents a strategic pivot toward specialty drug and medical‑food offerings, but investors will watch closely how the company translates this initiative into revenue growth amid ongoing financial headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.